STALICLA, a clinical stage drug discovery company specializing in neuroscience, has partnered with neuroimaging company Firefly Neuroscience to conduct further validation of electroencephalogram (EEG)-based biomarkers in specific patient subgroups with autism spectrum disorder (ASD). This collaboration follows the completion of STALICLA's Phase Ib clinical trial for its lead asset, STP1, which demonstrated that EEG measurement is a strong predictor of efficacy.

The collaboration between STALICLA and Firefly Neuroscience is expected to enhance EEG validation as a biomarker for ASD in specific patient subgroups. STALICLA's Databased Endophenotyping Patient Identification (DEPI) platform has shown its efficacy with various clinical trials and successfully identified two groups of ASD patients, leading to the development of customized treatments STP1 and STP2. The use of the Brain Network Analytics (BNA) platform in conjunction with DEPI-driven subgroups of ASD patients will further validate EEG measurements and DEPI's ability to classify patients and predict their response to treatment for ASD.

STALICLA is focused on developing a precision medicine drug discovery platform called DEPI, which caters to patients suffering from neurodevelopmental and neuropsychiatric disorders. The company’s pipeline has two drug targets, both of which treatments are scheduled to enter Phase II clinical trials in 2023.